02185nas a2200241 4500008004100000245008800041210006900129260001200198300001200210490000600222520145100228653001801679653001301697653002501710653002201735653001501757100002201772700002401794700002701818700002601845700003701871856003501908 2016 eng d00aInhibition of MDR1 in mammary cell carcinoma reverses Multidrug Resistance by SOCS10 aInhibition of MDR1 in mammary cell carcinoma reverses Multidrug  c09/2015 a103-1120 v83 a

Introduction: Suppressors of cytokine signalling (SOCS1), a newly indentified antiapoptotic molecule is a downstream effector of the receptor tyrosine kinase-Ras signalling pathway. Current study has uncovered that SOCS1 may have wide and imperative capacities, particularly because of its close correlation with malignant tumors. Methods: To investigate the impact of SOCS1 on MDR, we analyzed the expression of P-gp and SOCS1 by immunohistochemistry and found there was positive correlation between them. At that point we effectively interfered with RNA translation by the contamination of siRNA of SOCS1 into MCF7/ ADM breast cancer cell lines through a lentivirus, and the expression of the target gene was significantly inhibited. Results: After RNAi the drug resistance was reduced altogether and the expression of MDR1 mRNA and P-gp in MCF7/ADM cell lines demonstrated a significant decrease. Likewise the expression of P53 protein increased in a statistically significant manner (p≤0.01) after RNAi exposure. Moreover, flow cytometry analysis uncovers that cell cycle and anti-apoptotic enhancing capacity of cells changed after RNAi treatment. Conclusion: These outcomes proposed SOCS1 may take part in breast cancer MDR by managing MDR1 and P53 expression, changing cell cycle and enhancing the anti-apoptotic ability of cells.

10aBreast cancer10aMDR1gene10aMultidrug resistance10aRNA interference.10aSOCS1 gene1 aPradhan, Debasish1 aTripathy, Gitanjali1 aPradhan, Rakesh, Kumar1 aPradhan, Shaktiprasad1 aMoharana, Soumyashree, Rupambika uhttps://phcogj.com/article/117